Everything below concerns lyophilisation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility class | Soluble in water and aqueous buffers | Stock solutions often prepared in sterile water |
| Typical storage temperature | Minus twenty degrees Celsius or below | Dry powder, protected from light |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Ultraviolet detection near 214 nanometres |
| Common synonyms | PT-141 and bremelanotide | Code and generic name used interchangeably |
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
=== Vaccine Impact Modelling Consortium === The Vaccine Impact Modelling Consortium (VMIC) consists of mathematical models of diseases to analyze the impact of Gavi's vaccines, mainly in terms of deaths averted and disability-adjusted life year loss prevented, and to help Gavi come up with ways to maximize the impact for a given amount of resources. It consists of several different groups of modellers working independently. In 2026, the VMIC published an analysis on the impact Gavi's vaccination programmes against 14 vaccine-preventable diseases across 117 low- and middle-income families. In terms of lives saved per 1000 vaccinations, HPV (11.24), measles (6.09), HepB (5.00), and malaria (2.78) were found to be the most imapctful. In terms of DALY-loss prevented per 1000 vaccinations, HPV (523.04), measles (411.01), malaria (203.04), and Hib (150.37) were the most impactful. This analysis describes the effect of increasing vaccination on top of an existing level of coverage and disease burden, so vaccinating against a disease that has already achieved herd immunity can appear less impactful.
Also in 2008, DiCaprio starred in Body of Lies, a spy film based on the novel of the same name. He played one of three agents battling a terrorist organization in the Middle East. Considering the film to be a throwback to political features of the 1970s like The Parallax View (1974) and Three Days of the Condor (1975), DiCaprio dyed his hair brown and wore brown contacts for the role. The film received mixed reviews from critics, and grossed $118 million against a budget of $67.5 million. Later in 2008, DiCaprio collaborated with Kate Winslet for the drama Revolutionary Road, directed by her then-husband Sam Mendes. As both actors had been reluctant to make romantic films similar to Titanic, it was Winslet who suggested that they both work with her on a film adaptation of the 1961 eponymous novel by Richard Yates. She found that the script, by Justin Haythe, had little in common with the 1997 blockbuster. Playing a couple in a failing marriage in the 1950s, DiCaprio and Winslet spent some time together in preparation, and DiCaprio felt claustrophobic on the small set they used. He saw his character as "unheroic", "slightly cowardly" and someone "willing to be just a product of his environment". Peter Travers liked DiCaprio's pairing with Winslet and his multi-layered portrayal of an overwhelmed character, and Marshall Sella of GQ called it the "most mature and memorable performance of his lifetime". DiCaprio earned his seventh Golden Globes nomination for the film. Revolutionary Road grossed $75.9 million against its budget of $35 million.
220 (5): 496.e1–496.e8. doi:10.1016/j.ajog.2019.01.218. PMID 30690015. S2CID 59342701. Sheng, C.; Jungverdorben, J.; Wiethoff, H.; Lin, Q.; Flitsch, L. J.; Eckert, D.; Hebisch, M.; Fischer, J.; Kesavan, J.; Weykopf, B.; Schneider, L.; Holtkamp, D.; Beck, H.; Till, A.; Wüllner, U.; Ziller, M. J.; Wagner, W.; Peitz, M.; Brüstle, O. (2018). "A Stably Self-Renewing Adult Blood-derived Induced Neural Stem Cell Exhibiting Pattern Ability and Epigenetic Rejuvenation". Nature Communications. 9 (1): 4047. Bibcode:2018NatCo...9.4047S. doi:10.1038/s41467-018-06398-5. PMC 6168501. PMID 30279449. López-Alcorocho, J. M.; Guillén-Vicente, I.; Rodríguez-Iñigo, E.; Guillén-Vicente, M.; Fernández-Jaén, T. F.; Caballero, R.; Casqueiro, M.; Najarro, P.; Abelow, S.; Guillén-García, P. (2019). "Study of Telomere Length in Preimplanted Cultured Chondrocytes". Cartilage. 10 (1): 36–42. doi:10.1177/1947603517749918. PMC 6376562. PMID 29322876. Salvador, L.; Singaravelu, G.; Harley, C. B.; Flom, P.; Suram, A.; Raffaele, J. M. (2016). "A Natural Product Telomerase Activator Lengthens Telomeres in Humans". Rejuvenation Research. 19 (6): 478–484. doi:10.1089/rej.2015.1793. PMC 5178008. PMID 26950204. Alda, M.; Puebla-Guedea, M.; Rodero, B.; Demarzo, M.; Montero-Marin, J.; Roca, M.; Garcia-Campayo, J. (2016). "Zen meditation, Length of Telomeres, and the Role of Experiential Avoidance and Compassion". Mindfulness. 7 (3): 651–659. doi:10.1007/s12671-016-0500-5. PMC 4859856. PMID 27217844. De Rooij, S. R.; Van Pelt, A. M.; Ozanne, S. E.; Korver, C. M.; Van Daalen, S. K.; Painter, R.
Sources: en.wikipedia.org
== Split == Chechens mediated in the settlement of the conflict between Jabhat al-Nusra (now — Hayat Tahrir al-Sham) and the Syrian opposition, on the one hand, and with ISIS, on the other. In early November 2014, the leadership of Jaish al-Muhajireen wal-Ansar, represented by Salahuddin Shishani, met with the leadership of ISIS in their capital Raqqa and held talks on reconciliation of the two warring parties. However, the conversation with the leadership of ISIS ended in vain as they chose to continue the conflict. In response to Shishani's proposal to stop the war between Sunni Muslims, in particular with Islamic Jamaats such as Jabhat al-Nusra, Ahrar al-Sham and others, the leadership of ISIS refused and stated that it would not stop fighting these groups, because it considers the emirs of these factions Kafirs and Murtads. After that, Shishani left Raqqa and returned to Idlib. This conflict was also reflected among the Chechen Mujahideen in Syria, in particular among the Chechen emirs, who had previously acted in alliance with each other. Some of them defected to the Islamic State and took leadership positions, while some remained on the side of Jabhat al-Nusra and the Syrian opposition. The very history of the conflict between Jabhat al-Nusra and ISIS (at that time, the Islamic State of Iraq) begins in the spring of 2013, when the emir of the Islamic State of Iraq which was Abu Bakr al-Baghdadi decided to expand his organisation into neighbouring Syria and to unite his territories in both the countries of Iraq and Syria.
Rosenthal, Anne M. (12 February 2003). "Murchison's Amino Acids: Tainted Evidence?". Astrobiology Magazine. Archived from the original on 30 August 2004. Matson, John (15 February 2010). "Meteorite That Fell in 1969 Still Revealing Secrets of the Early Solar System". Scientific American. This article incorporates public domain material from websites or documents of the National Aeronautics and Space Administration.
Psoriatic JIA typically presents in children between the ages of 2-4 and 10 and up, having a bi-modal age of onset. 50% of children with psoriatic JIA develop psoriasis. Adolescents and older children have a similar presentation to psoriatic arthritis (the adult continuation of this type of JIA). Treatment consists of synthetic DMARDs such as methotrexate or TNF-α inhibitors. DMARDs targeting inflammatory cytokines IL-17, IL-12, or IL-23 may be used. Systemic JIA is characterized by markedly elevated inflammatory markers, fevers, and rashes. It may also present as lymph node swelling, hepatosplenomegaly (swelling of the liver and spleen), and as a life-threatening hyperinflammation syndrome known as macrophage activation syndrome. Early treatment with IL-1 and IL-6 inhibitors may induce remission. DMARDs combined with systemic steroids may be needed in severe inflammation or macrophage activation syndrome. Systemic JIA is pathologically similar to Adult-Onset Still's Disease, and this is thought to be the adult continuation of the same disease.
In hemodialysis, the patient's blood is pumped through the blood compartment of a dialyzer, exposing it to a partially permeable membrane. The dialyzer is composed of thousands of tiny hollow synthetic fibers. The fiber wall acts as the semipermeable membrane. Blood flows through the fibers, dialysis solution flows around the outside of the fibers, and water and wastes move between these two solutions. The cleansed blood is then returned via the circuit back to the body. Ultrafiltration occurs by increasing the hydrostatic pressure across the dialyzer membrane. This usually is done by applying a negative pressure to the dialysate compartment of the dialyzer. This pressure gradient causes water and dissolved solutes to move from blood to dialysate and allows the removal of several litres of excess fluid during a typical 4-hour treatment. In the United States, hemodialysis treatments are typically given in a dialysis center three times per week (due in the United States to Medicare reimbursement rules); however, as of 2005 over 2,500 people in the United States are dialyzing at home more frequently for various treatment lengths. Studies have demonstrated the clinical benefits of dialyzing 5 to 7 times a week, for 6 to 8 hours. This type of hemodialysis is usually called nocturnal daily hemodialysis and a study has shown it provides a significant improvement in both small and large molecular weight clearance and decreases the need for phosphate binders.
Sources: en.wikipedia.org
Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.
Cycling between frozen and thawed states promotes aggregation and can reduce the amount of soluble peptide. Adsorption to container walls also removes material from solution over time. Suppliers generally recommend aliquoting before freezing to limit the number of cycles.
A typical certificate lists lot number, appearance, purity by chromatographic area, identity confirmation and the analytical methods used. Some suppliers add endotoxin or residual solvent results. The document describes the tested lot only and does not extend to other batches.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.